Brilliant Violet 421™ anti-human CD106
Description
CD106 is a 110 kD single chain type I glycoprotein also known as VCAM-1 and INCAM-110. It is expressed predominantly on activated vascular endothelium but has also been identified on follicular and interfollicular dendritic cells, some macrophages, bone marrow stromal cells, and non-vascular cell populations within joints, kidney, muscle, heart, placenta, and brain. Expression on endothelial cells as well as many other cells is induced by inflammatory stimuli and cytokines. Activated endothelial cells can release soluble forms of CD106 which can be detected in the blood. CD106 binds the integrins CD49d/CD29 (VLA-4) and α4β7 that contribute to leukocyte adhesion, transmigration, and co-stimulation of T cell proliferation.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.